Mikhail Eropkin

Prof. Mikhail Eropkin

Etiology and epidemiology, Research Institute of Influenza, St Petersburg, Russia
orcid

Research Focus & Metrics

Academic Career Length

51Years (1976-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2013 in Science
Verified
Journal Article
Closed access
PDF file
BKBjörn F. Koel
Björn F. Koel
DBDavid Burke
David Burke
TBTheo M. Bestebroer
Theo M. Bestebroer
SVStefan van der Vliet
Stefan van der Vliet
GZGerben C. M. Zondag
Gerben C. M. Zondag
DSDerek Smith
Derek Smith
Flu Drift Limited: Five antigenic sites in the virus surface hemagglutinin protein, which together comprise 131 amino acid positions, are thought to determine the full scope of antigenic drift of influenza A virus. Koel et al. (p. 976 ) show that major antigenic change can be caused by single amino acid substitutions. These single substitutions substantially skew the way the immune system “sees” the virus. All substitutions of importance are located next to the receptor-binding site in the hemagglutinin. Because there are few positions of importance for antigenic drift, there are strict biophysical limitations to the substitutions at these positions, which restricts the number of new antigenic drift variants at any point in time. Thus, the evolution of influenza virus may be more predictable than previously thought.

1 January 1983 in Hoppe-Seyler´s Zeitschrift Für Physiologische Chemie
Verified
Journal Article
Closed access
VTVito Turk
Vito Turk
JBJože BRZIN
Jože BRZIN
MLMira Longer
Mira Longer
ARAnka Ritonja
Anka Ritonja
MEMikhail Eropkin
Mikhail Eropkin
WMWerner Machleidt
Werner Machleidt
Article Protein Inhibitors of Cysteine Proteinases. III. Amino-Acid Sequence of Cystatin from Chicken Egg White was published on January 1, 1983 in the journal Biological Chemistry (volume 364, issue 2).

1 October 2018 in Antiviral Research
Verified
Journal Article
Open access
JRJ.L. Romette
J.L. Romette
CPC.M. Prat
C.M. Prat
EGE.A. Gould
E.A. Gould
XLX. de Lamballerie
X. de Lamballerie
Remi CharrelRemi Charrel
Remi Charrel
PLP. Lieutaud
P. Lieutaud
The European Virus Archive (EVA) was created in 2008 with funding from the FP7-EU Infrastructure Programme, in response to the need for a coordinated and readily accessible collection of viruses that could be made available to academia, public health organisations and industry. Within three years, it developed from a consortium of nine European laboratories to encompass associated partners in Africa, Russia, China, Turkey, Germany and Italy. In 2014, the H2020 Research and Innovation Framework Programme (INFRAS projects) provided support for the transformation of the EVA from a European to a global organization (EVAg). The EVAg now operates as a non-profit consortium, with 26 partners and 20 associated partners from 21 EU and non-EU countries. In this paper, we outline the structure, management and goals of the EVAg, to bring to the attention of researchers the wealth of products it can provide and to illustrate how end-users can gain access to these resources. Organisations or individuals who would like to be considered as contributors are invited to contact the EVAg coordinator, Jean-Louis Romette, at jean-louis.romette@univmed.fr.

1 May 2013 in Pharmaceutical Chemistry Journal
Verified
Journal Article
Closed access
PDF file
MEMikhail Eropkin
Mikhail Eropkin
EME. Yu. Melenevskaya
E. Yu. Melenevskaya
KNK. V. Nasonova
K. V. Nasonova
TBT. S. Bryazzhikova
T. S. Bryazzhikova
EEE. M. Eropkina
E. M. Eropkina
OKO. I. Kiselev
O. I. Kiselev

27 May 2016 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
AKAndrey Komissarov
Andrey Komissarov
AFArtem Fadeev
Artem Fadeev
MSMariia V. Sergeeva
Mariia V. Sergeeva
SPSergey Petrov
Sergey Petrov
KKKseniia Komissarova
Kseniia Komissarova
MGMikhail Grudinin
Mikhail Grudinin
A dramatic increase of influenza activity in Russia since week 3 of 2016 significantly differs from previous seasons in terms of the incidence of influenza and acute respiratory infection (ARI) and in number of lethal cases. We performed antigenic analysis of 108 and whole‐genome sequencing of 77 influenza A(H1N1)pdm09 viruses from Moscow and Saint Petersburg. Most of the viruses were antigenically related to the vaccine strain. Whole‐genome analysis revealed a composition of specific mutations in the internal genes (D2E and M83I in NEP, E125D in NS1, M105T in NP, Q208K in M1, and N204S in PA‐X) that probably emerged before the beginning of 2015/2016 epidemic season.

22 August 2022 in Frontiers in Medicine
Verified
Journal Article
Open access
OSOlesia Schapovalova
Olesia Schapovalova
AGAnna Gorlova
Anna Gorlova
JMJohannes de Munter
Johannes de Munter
ESElisaveta Sheveleva
Elisaveta Sheveleva
MEMikhail Eropkin
Mikhail Eropkin
CSCareen A. Schroeter
Careen A. Schroeter
Background: While all efforts have been undertaken to propagate the vaccination and develop remedies against SARS-CoV-2, no satisfactory management of this infection is available yet. Moreover, poor availability of any preventive and treatment measures of SARS-CoV-2 in economically disadvantageous communities aggravates the course of the pandemic. Here, we studied a new immunomodulatory phytotherapy (IP), an extract of blackberry, chamomile, garlic, cloves, and elderberry as a potential low-cost solution for these problems given the reported efficacy of herbal medicine during the previous SARS virus outbreak.Methods: The key feature of SARS-CoV-2 infection, excessive inflammation, was studied in in vitro and in vivo assays under the application of the IP. First, changes in tumor-necrosis factor (TNF) and lnteurleukin-1 beta (IL-1β) concentrations were measured in a culture of human macrophages following the lipopolysaccharide (LPS) challenge and treatment with IP or prednisolone. Second, chronically IP-pre-treated CD-1 mice received an agonist of Toll-like receptors (TLR)-7/8 resiquimod and were examined for lung and spleen expression of pro-inflammatory cytokines and blood formula. Finally, chronically IP-pre-treated mice challenged with LPS injection were studied for “sickness” behavior. Additionally, the IP was analyzed using high-potency-liquid chromatography (HPLC)-high-resolution-mass-spectrometry (HRMS).Results: LPS-induced in vitro release of TNF and IL-1β was reduced by both treatments. The IP-treated mice displayed blunted over-expression of SAA-2, ACE-2, CXCL1, and CXCL10 and decreased changes in blood formula in response to an injection with resiquimod. The IP-treated mice injected with LPS showed normalized locomotion, anxiety, and exploration behaviors but not abnormal forced swimming. Isoquercitrin, choline, leucine, chlorogenic acid, and other constituents were identified by HPLC-HRMS and likely underlie the IP immunomodulatory effects.Conclusions: Herbal IP-therapy decreases inflammation and, partly, “sickness behavior,” suggesting its potency to combat SARS-CoV-2 infection first of all via its preventive effects.